Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis

Armen Hareyan's picture

Multiple Sclerosis Drug

Biogen Idec and Elan Corporation, plc announced that data to be presented today at the Academy of Managed Care Pharmacy's (AMCP) 2006 Educational Conference in Chicago, IL show that in Phase III studies TYSABRI(R) (natalizumab) therapy significantly reduced corticosteroid use and hospitalizations, and increased the proportion of

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.